Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches. by Acaster, S. et al.
Acaster et al. Health and Quality of Life Outcomes  (2015) 13:33 
DOI 10.1186/s12955-015-0224-6RESEARCH Open AccessMapping the EQ-5D index from the cystic fibrosis
questionnaire-revised using multiple modelling
approaches
Sarah Acaster1*, Binny Pinder1, Clara Mukuria2 and Amanda Copans3Abstract
Background: This study was designed to develop a mapping algorithm to estimate EQ-5D utility values from Cystic
Fibrosis Questionnaire-Revised (CFQ-R) data.
Methods: A cross-sectional survey of adults with cystic fibrosis (CF) was conducted in the UK. The survey consisted
of the CFQ-R, the EQ-5D and a background questionnaire. Eight regression models, exploring item and domain level
predictors, were evaluated using three different modelling approaches: ordinary least squares (OLS), Tobit, and a two-part
model (TPM). Predictive performance in each model was assessed by intraclass correlations, information criteria (Bayesian
information criteria and Alkaike information criteria), and root mean square error (RMSE).
Results: The survey was completed by 401 participants. For all modelling approaches the best performing item
level model included all items, and the best performing domain level model included the CFQ-R Physical-, Role- and
Emotional-functioning, Vitality, Eating Disturbances, Weight, and Digestive Symptoms domains and a selection of
squared terms. Overall, the item level TPM, including age and gender covariates performed best within sample
validation, but OLS and TPM domain models with squared terms performed best out-of-sample and are recommended
for mapping purposes.
Conclusions: Domain and item level models using all three modelling approaches reached an acceptable degree of
predictive performance with domain models performing well in out-of-sample validation. These mapping functions can
be applied to CFQ-R datasets to estimate EQ-5D utility values for economic evaluations of interventions for patients
with cystic fibrosis. Further research evaluating model performance in an independent sample is encouraged.
Keywords: Mapping, Health utilities, CFQ-R, EQ-5D, Quality of lifeBackground
Cystic fibrosis (CF) is a hereditary and life-threatening
autosomal recessive disorder. An estimated 80,000 chil-
dren and young adults suffer with CF worldwide, with a
rate of 1 case per 2,500 births [1]. If untreated, patients
are likely to suffer from chronic respiratory infections,
pancreatic enzyme insufficiency and associated compli-
cations. Advances in treatment and management have
resulted in an increase in survival rates. The predicted
median age of survival for a person with CF is the late
30s, and with over half of children born in the 1990s* Correspondence: sarah@acaster.org
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unless otherwise stated.expected to survive into their fifth decade [2]. Despite
these advances though the disease still represents a very
significant burden for patients in terms of their symp-
toms, loss of functioning and poor health related quality
of life (HRQL) [3].
HRQL is a multi-dimensional concept, which reflects
individual’s subjective evaluation of his or her daily func-
tioning (i.e. physical, psychological, emotional and social
functioning) and well-being. Poor lung functioning [Forced
Expiratory Volume in 1 second (FEV1) < 30% predicted]
and pulmonary exacerbations in the past 6 months have
been related to poor HRQL [4,5]. The Cystic Fibrosis
Questionnaire-Revised (CFQ-R) is a validated patient-
reported outcome (PRO) measure of HRQL specifically
designed for individuals with CF [6,7]. The CFQ-R is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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demonstrated responsiveness [8,9], and been used to
support PRO label claims.
Decision makers within drug licensing authorities
such as the US Food and Drug Administration (FDA)
and payers such as the National Institute for Health &
Care Excellence (NICE) in the UK have become increas-
ingly interested in the information that can be captured
from HRQL PROs. NICE and many other health tech-
nology assessment bodies globally, are interested in
understanding the benefits of health technologies in
terms of quality-adjusted life years (QALYs): a metric
incorporating length and quality of life. Estimating
QALY requires a specific type of HRQL data that re-
flects the value that people place on HRQL rather than
just a psychometric score. This value is referred to as
utility and is measured on a scale of 0 (dead) to 1 (full
health). UK national guidelines regarding the data used
in health technology appraisals recommend the use of
generic preference-based measures to capture utility,
with a stated preference for the EQ-5D questionnaire
[10]. However these data are not always collected in
clinical trials. To address this data gap it is possible to
estimate EQ-5D scores from a different PRO, such as
the CFQ-R, with the development of a robust mapping
algorithm. Mapping studies often also incorporate
demographic characteristics into model estimation to
increase a models predictive performance [11-13]. This
approach is endorsed by NICE [14] and there is a grow-
ing body of literature related to the development of
mapping functions linking source disease specific HRQL
measures onto target preference-based measured using
regression models [15].
The present study was designed to develop a mapping
algorithm to estimate EQ-5D utility values from CFQ-R
data, with and without adjustment for demographic
characteristics (age and gender). This will enable existing
and future trial datasets, which include CFQ-R (but not
EQ-5D), to be used by decision makers to understand
the value of new health technologies in CF.
Materials and methods
Study design and participants
A cross-sectional observational study conducted as an
on-line survey was undertaken in the UK. The option to
complete a pen and paper survey through the post was
provided but not utilised by any respondents. The survey
was advertised by the Cystic Fibrosis Trust (CF Trust)
by placing adverts on the CF Trust website, forum,
Facebook page, Twitter account and Google Adword.
Potential respondents were informed that the CF Trust
would receive a £50 donation for every completed survey;
respondents did not receive any direct remuneration for
their participation.All participants had a self-reported clinical diagnosis
of CF, were aged 18 years or above and currently resi-
dent in the UK. Participants were also asked to rate their
CF severity as mild, moderate or severe during screening
to ensure sample variability in HRQL item responses.Ethics
Independent ethical review was sought and granted by
Schulman Associates Independent Institutional Review
Board Inc. Informed consent was obtained from all par-
ticipants prior to completion of the online survey.Survey
Interested participants followed a link provided by the
CF Trust to be taken to an information sheet describing
the purpose of the survey, the consent form and the sur-
vey. The survey was conducted from January – March
2012. The survey consisted of three questionnaires: the
CFQ-R, the EQ-5D, and a demographic/clinical back-
ground form. Each of these measures is descried in more
detail below.CFQ-R
The CFQ-R is a validated disease-specific questionnaire
measuring health-related quality of life in CF patients
[6,7]. The teen/adult UK English version of the question-
naire, suitable for ages 14+, was used. This consists of
50 items across 12 domains: ‘physical functioning’, ‘role
functioning’, ‘emotional functioning’, ‘vitality’, ‘social
functioning’, ‘body image’, ‘eating disturbances’, ‘treat-
ment burden’, ‘health perceptions’, ‘weight’, ‘respiratory
symptoms’, and ‘digestive symptoms’. All items use cat-
egorical response options, with values ranging from 1 – 4.
Domain scores were calculated using the developer’s
guidelines, which produces a potential range of scores
from 0–100, with higher scores indicting better HRQL.EQ-5D
The EQ-5D-3L is a generic preference-based measure
of HRQL [16-18]. The questionnaire consists of five
domains: ‘mobility’, ‘self-care’, ‘usual activity’, ‘pain/
discomfort’, and ‘anxiety/depression’. Participants also
indicate their current health on a visual analogue scale
ranging from 0 (worst imaginable health state) to 100
(best imaginable health state). Health utilities were
derived from the EQ-5D using UK general population
preference weights [19], which provide a potential range
of scores from - 0.59 to 1.0; a score of 1 represents full
health, a score of 0 represents a state equivalent to dead,
and a score below 0 represents a state worse than dead.
NICE state that EQ-5D is the preferred source of utility
values for use in economic evaluation [10].
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The demographic/clinical background form gathered
data on respondents’ age, sex, ethnicity, employment
status, time since CF diagnosis, FEV1 (if known), date of
last FEV1 assessment, and exacerbation occurrence since
last FEV1 assessment.
None of the respondents had missing data in the
EQ-5D, CFQ-R, age or gender.
Analysis
Model development and specifications
Figure 1 shows the distribution of EQ-5D utility scores,
which was used to determine which modelling ap-
proaches to use. 19% had a score of 1 (i.e. full heath)
while 3% had a score less than 0. Three regression
modelling approaches were used to identify the most
parsimonious prediction model with the best fit: an
ordinary least squares (OLS) model, a Tobit model, and
a two-part model (TPM). The OLS approach is used to
estimate the unknown parameters in a linear regression
model by minimizing the sum of squared errors from
the data. This model has frequently been identified as
the most parsimonious and best fitting model in utility
mapping studies when compared to other methods
designed to cope with bounded and multi-modal distri-
butions [15,20]. The Tobit model (also known as the
censored regression model) takes better account of the
censored nature of EQ-5D data, deals with truncated
data and can approximate for skewed data by setting
the upper limit to 1. Censored least absolute deviation
(CLAD) models have also been advocated to deal with
censoring but these are median-based models while
most economic evaluation models are mean-based [14]0
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Figure 1 Histogram of EQ-5D utility scores.therefore CLAD was not assessed. The TPM approach
deals with the high proportion of values are at 1.0
[21-23]. The first part of the two-part model uses a logit
regression to estimate the probability that an individual is
in full health. The second part estimates EQ-5D utilities
for remaining observations using a truncated OLS model
which can lie between −0.594 and 0.99. The two parts of
the model are combined using the expected value method
to calculate the EQ-5D score as:
EV EQ−5Dð Þ ¼ P EQ−5D ¼ 1ð Þ  1½ 
þ P EQ−5D≠1ð Þ  Predicted EQ−5D part 2½ 
[EV = Expected value; P(EQ-5D = 1) = Probability of be-
ing at score 1 predicted from part 1; (P(EQ-5D ≠ 1) = 1- P
(EQ-5D = 1), probability of not being at 1; Predicted
EQ-5D part 2 = predicted EQ-5D from a truncated OLS
regression for those who score less than 1].
Based on recommendations in the literature [14],
separate models were tested for the CFQ-R domains and
items were used to predict EQ-5D utility scores using
the three modelling approaches. The CFQ-R Health
domain and its constituent items were not selected for
the regression models as all of the remaining CFQ-R
items also measured health; thus these items would
either be redundant or cause problems of multicollinear-
ity which would violate the regression assumptions and
render the model unreliable. Item 43 (How has your
mucus been?) from the CFQ-R was also removed from
the regression analysis as this item was a sub-question
which not all participants provided a response. Gender
and age were also included in one of the regression
specifications for all three models. Self reported FEV1.5 1
tility Value
Acaster et al. Health and Quality of Life Outcomes  (2015) 13:33 Page 4 of 11was not included in any models as the aim was to estimate
a mapping function specifically from the CFQ-R, rather
than a combination of measures of CF. In total, eight
different sets of independent variables were evaluated to
ensure the best model specification was selected and re-
peated using OLS, Tobit and TPM mapping methods:
Model 1: All CFQ-R domains excluding the health
domain
Model 2: CFQ-R domains that are statistically significant
at the 10% level
Model 3: Model 2 + statistically significant squared terms
Model 4: Model 3 + interaction terms
Model 5: All CFQ-R items excluding the health domain
items
Model 6: CFQ-R items that are statistically significant
at the 10% level
Model 7: Model 6 with collapsed unordered items
Model 8: Best fitting model + gender and age
In all item level models, the items were reverse coded
if appropriate, and dummy coded with a score of 1 (poor
health) as the reference category. In Model 7 unordered
items (where coefficients did not follow the predicted
order of magnitude across good to poor response options)
were dichotomised to ‘no problems’ versus ‘other’. In the
TPM model, item level models were also collapsed to 2 or
3 levels for those in full health.
The Ramsey Regression Equation Specification Error
Test was used to assess misspecification in the linear
models obtained using OLS. The linktest was used to
assess misspecification in the Tobit model and the sec-
ond part of the TPMs. Multicollinearity was assessed
using the variance inflation factor (VIF) with values
greater than 10 indicating a problem. Bootstrapped
bias-corrected (2000 replications) or robust standard
errors are reported for all models.
Model validation and comparison
Model goodness of fit was assessed by adjusted/pseudo
R2 statistics (OLS and Tobit models only), Bayesian in-
formation criteria (BIC) and Alkaike information criteria
(AIC) statistics. Lower BIC and AIC values would indi-
cate a better fitting model. To examine the predictive
performance of the model the differences between the
predicted and observed EQ-5D scores at the individual
level were examined by computing the mean squared
error (MSE) and root MSE (RMSE). Smaller error values
are indicative of better performing models. Plots of the
observed and predicted EQ-5D scores are used to examine
the performance of the models. Predicted and observed
EQ-5D utility scores and RMSE were also compared
across different EQ-5D ranges and CF severity as mea-
sured by percentage of predicted FEV1 (FEV1 groups:mild = >70%, moderate = 70% - 41%, severe = < 41%).
ANOVA models were used to examine differences in
predicted scores across EQ-5D ranges and FEV1 severity
groups. Intra-class correlations, which measure the level
of agreement between the predicted and observed
scores, were also assessed.
It is recommended that where possible an external
dataset is used as a validation dataset to determine the
accuracy of predicted utility values of the selected
models out-of-sample [14]. However, no external data-
set was available for the present study and therefore the
performance of the mapping algorithms were assessed
using a cross-validation approach. The sample was
randomly split into four groups of 25% each. The best
fitting models within sample were re-run on three of
the four group and applied to the excluded group to
ensure in an iterative process until each of the samples
had been used as both estimation and validation sam-
ples. 75% of the data were used as an estimation dataset
for building models, and 25% were used as a validation
dataset. The proportion of responses for the estimation
dataset is larger than for the validation dataset to
enhance model accuracy with a greater number of
responses.
All regression analyses were conducted using STATA v 11.
Results
Sample characteristics
A total of 401 participants completed the survey; all
surveys were completed online. The demographic and
clinical characteristics of participants, by FEV1 severity
group and for the sample as a whole, are presented in
Table 1. The sample represented a broad range in terms
of demographics and disease severity.
Descriptive statistics for EQ-5D and CFQ-R
Observed EQ-5D utility and CFQ-R domain scores
of the participants are shown in Table 2. The mean
EQ-5D score was 0.67 (SD = 0.28), ranging from –
0.35 to 1, which is only slightly narrower than the
theoretical range of – 0.59 to 1. Both the EQ-5D
and CFQ-R mean scores reflect the self-reported dis-
ease severity as measured by FEV1, with utility and
almost all CFQ-R domain scores declining with in-
creased severity. The digestive symptoms domain
was the only domain not reflecting FEV1 severity.
Regression modelling
24 models were explored in total (8 specifications for
OLS, Tobit and TPM), the goodness of fit and predictive
performance statistics from the best domain and item
level model for each regression type are presented in
Table 3. The identification of the best domain and item
level models was based on an examination of all
Table 1 Demographic and clinical characteristics of the
study participants
Characteristic Statistic
N 401
Age Mean ± SD 28.7 ± 8.88
Range (min, max) 18 - 62
Sex Male: N (%) 156 (38.9)
Ethnicity (N %) White 393 (98.0)
Other 8 (2.0)
Working/studying Yes: N (%) 248 (49.4)
Diagnosis of CF (years) Mean ± SD 25.3 ± 9.1
Median 25.0
Range (min, max) 1 - 59
Recent FEV1 Predicted Mean ± SD 65.7 ± 27.3
Median 67.0
Range (min, max) 17 - 99
Last FEV1: N (%) 0 – 1 month 242 (63.9)
>1 - 3 months 97 (25.6)
>3 months 11 (2.9)
Recent Exacerbation: N (%) Yes 114 (30.1)
Requiring Hospitalisation N (%) of above 42 (36.8)
N, sample size; SD, Standard Deviation; FEV1, percentage of predicted Forced
Expiratory Volume in 1 second.
FEV1 severity levels: Mild = >70%; Moderate = 41% – 70%; Severe = < 41%.
Table 2 EQ-5D and CFQ-R descriptive data - total sample and
Mild FEV1 Mod
Mean ± SD Mea
EQ-5D
Utility value 0.74 ± 0.27 0.70
CFQ-R
Physical functioning 67.18 ± 28.82 44.74
Role functioning 71.83 ± 25.25 60.17
Vitality 47.78 ± 23.06 41.09
Emotional functioning 62.54 ± 25.49 57.89
Social functioning 61.06 ±17.84 55.06
Body image 64.23 ± 28.07 61.84
Eating disturbance 77.35 ± 25.22 76.32
Treatment burden 56.30 ± 23.68 44.83
Health perceptions 58.94 ± 26.43 43.45
Weight 69.52 ± 36.43 63.91
Respiratory symptoms 61.00 ± 24.68 47.82
Digestive symptoms 67.30 ± 24.65 71.80
SD, standard deviation; FEV1, percentage of predicted Forced Expiratory Volume in
FEV1 severity levels: Mild = >70%; Moderate = 41% – 70%; Severe = < 41%.
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The performance statistics of the 18 models not pre-
sented are available upon request.
In the OLS, Tobit and TPM regressions, the best per-
forming domain level model within sample was model 3:
including statistically significant domains at the 10%
level, plus significant squared terms. There was no
evidence of multicollinearity in any of the domain level
models (mean and individual variable VIF < 10) apart
from where expected when squared terms are included.
There was evidence of misspecification in all the OLS
models including model 3 but the Tobit and TPM model
3 were not misspecified. The best performing item level
model within sample was model 5 (all CFQ-R items in-
cluded in analysis) for OLS, Tobit and TPM; however,
the TPM model 5 was improved with the addition of age
and gender as covariates (model 8). Item level models
had mean VIF <10 but some individual dummy variables
(19/139) had VIF greater than 10 which indicates prob-
lems with multicollinearity when all items were included.
Item level models also had evidence of misspecification
for all models apart from model 7.
As shown in Table 3 all six best performing models
demonstrated good predictive performance within sample;
all predicted means (0.671 – 0.691) were within 0 – 0.02
of the observed mean (0.671), and the fitted ranges of the
EQ-5D preference-based values were within 0.128 – 0.296
of the lower bound observed value (−0.349). As would
be expected only OLS models exceeded the upper
bound observed value of 1. In all instances the item
level models performed marginally better than thesplit by FEV1 severity levels
erate FEV1 Severe FEV1 Total sample
n ± SD Mean ± SD Mean ± SD
± 0.26 0.54 ± 0.29 0.67 ± 0.28
± 26.01 20.63 ± 18.24 45.71 ± 30.83
± 24.00 41.87 ± 26.19 59.87 ± 27.54
± 20.78 31.73 ± 17.68 40.69 ± 21.74
± 22.47 49.64 ± 19.82 57.47 ± 23.44
± 19.26 50.94 ± 20.51 56.12 ± 19.35
± 27.27 43.91 ± 29.75 58.38 ± 28.96
± 25.33 65.73 ± 28.89 74.70 ± 26.28
± 23.87 42.17 ± 22.61 49.40 ± 25.2
± 21.23 24.90 ± 22.66 44.25 ± 26.16
± 39.77 42.17 ± 40.35 60.76 ± 40.29
± 21.48 38.55 ± 21.8 49.63 ± 24.44
± 25.63 73.49 ± 22.00 71.27 ± 23.92
1 second.
Table 3 Summary of model performance for best OLS Tobit and TPM Item and domain models
Observed
EQ-5D
OLS models Tobit models TPM models
Domain (3) Item (5) Domain (3) Item (5) Domain (3) Item (8)
Mean 0.671 0.671 0.671 0.672 0.672 0.691 0.679
SD 0.282 0.223 0.245 0.225 0.250 0.236 0.254
Range of values - 0.349 - 1 - 0.099 - 1.04 - 0.165 - 1.183 - 0.053 - 0.985 - 0.167 - 1 - 0.221 - 0.985 - 0.200 - 1
ICC 0.715 0.801 0.716 0.811 0.717 0.820
RMSE - 0.127 0.111 0.173 0.136 0.127 0.096
MSE - 0.030 0.029 0.030 0.018 0.029 0.017
BIC - −214 383 45 626 256, − 201 574, 379
AIC - −254 −173 5 71 240, − 247 270, − 150
OLS, ordinary least squares; TPM, two-part model; SD, standard deviation; Adj. R2, adjusted R2; RMSE, root of the mean square error; MSE, mean square error; AIC,
Akaike information criterion; BIC, Bayesian information criterion.
Model 3 = CFQ-R domains that are statistically significant at the 10% level + statistically significant squared terms; Model 5 = All CFQ-R items excluding the health
domain items; TPM Model 8 = All CFQ-R items excluding the health domain items + age and gender.
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(>0.7) between predicted and observed EQ-5D values.
This is further illustrated in Figure 2 and Table 4, where
the mean observed and predicted EQ-5D preference-
based values by health state ranking indicate over
prediction for more severe health states (where the
observed EQ-5D value was less than 0.3), and under
prediction for very mild health states (where the
observed EQ-5D value was above 0.9). However, Table 4
also illustrates that all six best performing domain and
item level models demonstrated responsiveness to
severity as assessed by EQ-5D and FEV1 sub-groups. There
were statistically significant differences (all p’s < 0.001)
across EQ-5D and FEV1 health states for each model’s
predicted EQ-5D values. The best performing within
sample model overall was the item level TPM, including
age and gender covariates. This model performed best
when predicting values across the range of EQ-5D ob-
served scores, did not include out of range predicted
values, and demonstrated good predictive performance
with the lowest RMSE values.
All 6 models were tested in the out-of-sample cross-
validation. A one way analysis of variance test indicated
no significant differences between the mean observed
EQ-5D values of the validation and estimation samples
across the 4 samples (F397,3 = 0.05, p = 0.985). Table 5
provides summary statistics of the observed and pre-
dicted EQ-5D utility scores in each of the four samples
based on models ran in the other 3 samples e.g. sample
1 predicted scores are based on models undertaken in
the combined 2 to 4 samples. Mean values tend to be
larger or smaller (difference 0.001 to 0.02) than the
observed mean values for most of the models with either
OLS and Tobit domain models (model 3) having the
smallest differences in samples 1 to 3 and TPM item
model (Model 8) having the smallest difference in
sample 4. In all the samples apart from sample 2, all themodels perform poorly at predicting the full observed
range particularly at the poor end of health (difference
0.03 to 0.62). In sample 2 the OLS item model (model 5)
and the TPM domain model (model 3) are within 0.004
of the observed minimum score. Tobit and TPM item
models (5 and 8) predict the maximum accurately while
OLS models predict values greater than 1 particularly in
the item models. In all the samples, RMSE is smallest in
the OLS and TPM domain models (0.118 to 0.146) and
largest in the TPM item level models (0.182 to 0.223).
ICC is larger in the domain models (0.50 to 0.81) com-
pared to the item models (0.29 to 0.56) indicating better
agreement between observed and predicted scores in the
former. Assessment of RMSE across the EQ-5D range
indicates that all models are poor at predicting at the
poor end of health but TPM item level models also have
larger RMSE in other parts of the EQ-5D range as well
(see the Additional file 1 detailing the results of Table 4
for each of the 4 cross-validation samples).
Based on RMSE and ICC and mean predicted values,
the OLS and TPM domain model (model 3) perform
best out-of-sample but are not good at predicting the
range of values. This contrasts with within sample pre-
dictions where TPM item model (model 8) performs
best. This may be in part due to poor performance of
these models when the samples are smaller as is the case
when running the models in only 75% of the sample.
However, the item models also have misspecification
and multicollinearity, which may increase the variation
in predicted scores. We therefore recommend the OLS
or TPM model 3 (Table 6) for generating EQ-5D utility
scores where they are not available.
Discussion
This study is the first attempt, to our knowledge, to
develop a mapping function to estimate EQ-5D preference-
based values from a condition-specific measure for patients
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Figure 2 Observed and Predicted EQ-5D for Best Fitting Item and Domain Models for OLS, Tobit and TPM.
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401 patients with different levels of disease severity
confirmed that EQ-5D preference–based values, or
utility values, can be estimated from the CFQ-R using
mapping functions. These predicted utility values can
be used to inform cost effectiveness models. The study
sample included a diverse range of CF severity, as mea-
sured by FEV1 and observed EQ-5D values, with good
sample sizes across FEV1 severity categories and close
to the full range of theoretical EQ-5D scores repre-
sented (1 to −0.35 versus 1 to −0.59). The range of
CFQ-R scores was also broad, with means from 21 – 77.
This represents a broader and more severe range than thatincluded in the CFQ-R validation (mean range = 51 – 92)
[24], but similar to that reported by Bradley et al. (mean
range = 25 – 85) [25]. The slight difference in ranges
may be due sampling methodology, which allowed
completion of the questionnaires in the privacy of the
patients’ home rather than on site, and as participants
were not recruited through clinics they may also repre-
sent a less adherent/controlled group. In addition our
sample only included adults (aged 18+), and had a
slightly higher proportion of females; age and female
gender having both been associated lower (worse heath)
scores [24]. As mapping is best supported by datasets
with a rectangular distribution to increase the predictive
Table 4 Summary of observed and predicted values by EQ-5D group and FEV1 severity
Observed EQ-5D
range
N Observed
EQ-5D
OLS models Tobit models TPM models
Domain (3) Item (5) Domain (3) Item (5) Domain (3) Item (8)
−0.349 - 0.099 23 −0.028 0.294 (0.321) 0.197 (0.225) 0.293 (0.320) 0.185 (0.214) 0.274 (0.307) 0.160 (0.196)
0.1 - 0.299 41 0.227 0.420 (0.211) 0.337 (0.149) 0.421 (0.209) 0.335 (0.148) 0.418 (0.214) 0.320 (0.134)
0.3 - 0.599 38 0.511 0.505 (0.130) 0.518 (0.106) 0.502 (0.136) 0.517 (0.113) 0.524 (0.135) 0.532 (0.100)
0.6 - 0.699 92 0.660 0.620 (0.106) 0.643 (0.093) 0.621 (0.110) 0.643 (0.098) 0.649 (0.115) 0.655 (0.092)
0.7 - 0.799 71 0.756 0.747 (0.084) 0.736 (0.088) 0.749 (0.093) 0.737 (0.097) 0.778 (0.099) 0.761 (0.089)
0.8 - 0.899 59 0.841 0.794 (0.109) 0.804 (0.097) 0.792 (0.103) 0.804 (0.100) 0.817 (0.101) 0.816 (0.099)
0.9 - 1 77 1 0.895 (0.107) 0.938 (0.088) 0.900 (0.100) 0.949 (0.051) 0.916 (0.084) 0.948 (0.052)
ANOVA F = 107.30 F = 176.10 F = 105.70 F = 183.84 F =104.81 F = 202.73
p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
FEV1
Severe < 41% 92 0.552 0.550 (0.157) 0.548 (0.132) 0.548 (0.158) 0.550 (0.133) 0.565 (0.157) 0.561 (0.121)
Moderate 41-70% 136 0.695 0.684 (0.119) 0.694 (0.107) 0.683 (0.120) 0.693 (0.101) 0.703 (0.120) 0.702 (0.099)
Mild > 70% 105 0.741 0.755 (0.113) 0.748 (0.097) 0.760 (0.116) 0.751 (0.090) 0.781 (0.111) 0.757 (0.076)
ANOVA F = 24.38 F = 19.29 25.39 F = 18.43 F = 23.83 F = 16.76
p< 0.001 p< 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
OLS, ordinary least squares; TPM, two-part model; FEV1, percentage of predicted Forced Expiratory Volume in 1 second.
Model 3 = CFQ-R domains that are statistically significant at the 10% level + statistically significant squared terms; Model 5 = All CFQ-R items excluding the health
domain items; TPM Model 8 = All CFQ-R items excluding the health domain items + age and gender.
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spectrum of scores, this diversity is likely to have
contributed to the consistently strong mapping results
seen across regression approaches and item and domain
level models.
Assessment of models within sample indicated that
the item level models (model 5) outperformed the
domain models in terms of predicting the mean, the
range, minimising RMSE and levels of agreement
with the observed EQ-5D utility scores. However,
item models suffered from misspecification and there
was evidence of some multicollinearity. Domain level
models with squared terms were better specified than
the item level models and had no problems with
multicollinearity apart from where expected in the
squared terms. The domain model with squared
terms also performed relatively well within sample in
terms of RMSE and ICC. Within sample predictions,
the TPM performed marginally better than the OLS
or Tobit models in terms of RMSE, ICC and the
range of predictions.
In the out-of-sample validation, testing of the best per-
forming domain (model 3) and item level models (model
5 or 8) showed that unlike within sample, domain level
models performed better in terms of predicting the
mean, minimising the RMSE and level of agreement
between observed and predicted scores based on ICC,
while item level models performed better in terms of
predicting the range of scores. OLS models were betterat predicting the mean and minimising the RMSE while
TPM models tended to have larger RMSEs. The TPM
models performed better in terms of ICC with slightly
higher ICCs in TPM model 3 compared to the same
model in OLS. Overall, the best performing models in
out-of-sample validation were the OLS and TPM do-
main models (model 3); these included the ‘physical
functioning’, ‘role functioning’, ‘emotion’, ‘vitality’, ‘eat’,
‘weight’, and ‘digestion’ domains. Thus, given the mis-
specification and multicollinearity problem associated
with item level models, these two domain models are
recommended for generating EQ-5D utility scores from
CFQ-R data when no utility data exists. These domain
model algorithms can be applied to item level data when
domain scores are generated, or when item level data is
not available as is often the case when effectiveness
information is drawn from published trial data.
When considering the ranges of the predicted values
of all mapping functions to the observed range of
EQ-5D values, there was a tendency of over prediction
in all models for observed values of EQ-5D lower than
0.3, and to a lesser extent, under prediction above
observed EQ-5D values > 0.9 both within sample and
in out-of-sample validation. Over prediction of low
preference-based values is not uncommon in the map-
ping literature when mapping to the EQ-5D [13,26,27].
The sample did not cover the full range of EQ-5D
scores and only a small proportion (3%) had scores
less than 0, which makes it difficult to accurately
Table 5 Out-of sample Cross validation of best fitting models - summary of observed and predicted values
EQ-5D OLS
model 3
OLS
model 5
Tobit
model 3
Tobit
model 5
TPM
model 3
TPM
model 5
Sample 1
N 97 97 97 97 97 97 97
Mean (SD) 0.6776 (0.277) 0.6755 (0.205) 0.6976 (0.252) 0.6717 (0.207) 0.6891 (0.238) 0.6932 (0.214) 0.6811 (0.270)
Range −0.3490 - 1 0.2702 - 1.028 0.1038 - 1.269 0.2539 - 0.9729 0.1444 - 1 0.1814 - 0.9734 0.0133, 1
RMSE 0.141 0.163 0.160 0.160 0.187 0.187
ICC 0.65 0.54 0.65 0.53 0.64 0.40
Sample 2
N 101 101 101 101 101 101 101
Mean (SD) 0.6632 (0.288) 0.6701 (0.243) 0.6744 (0.297) 0.6683 (0.246) 0.6744 (0.297) 0.6868 (0.263) 0.6785 (0.329)
Range −0.1810 - 1 −0.0399 - 1.006 −0.1850 - 1.242 −0.0040 - 0.981 −0.2001 - 1 −0.1830 - 0.9838 −0.1642, 1
RMSE 0.118 0.165 0.162 0.162 0.182 0.182
ICC 0.79 0.61 0.79 0.64 0.79 0.50
Sample 3
N 100 100 100 100 100 100 98
Mean (SD) 0.6742 (0.277) 0.6696 (0.202) 0.6791 (0.221) 0.6779 (0.210) 0.6808 (0.236) 0.6954 (0.214) 0.6886 (0.252)
Range −0.1810 - 1 0.2417 - 0.9782 0.0777 - 1.193 0.2592 - 0.9824 −0.0555 - 1 0.2593 - 0.9837 0.1442, 1
RMSE 0.146 0.196 0.204 0.204 0.223 0.223
ICC 0.50 0.31 0.52 0.29 0.49 0.29
Sample 4
N 103 103 103 103 103 103 103
Mean (SD) 0.6688 (0.287) 0.6703 (0.238) 0.6515 (0.281) 0.6703 (0.237) 0.6526 (0.302) 0.6887 (0.248) 0.6678 (0.295)
Range −0.3310 - 1 −0.0577 - 1.048 −0.2275 - 1.201 −0.0441 - 0.9839 −0.2964 - 1 −0.1583 - 0.9879 −0.1745, 1
RMSE 0.120 0.185 0.180 0.180 0.207 0.207
ICC 0.80 0.51 0.81 0.56 0.81 0.47
OLS, ordinary least squares; TPM, two-part model; SD, standard deviation; ICC, Intraclass correlation; RMSE, root of the mean square error.
Model 3 = CFQ-R domains that are statistically significant at the 10% level + statistically significant squared terms; Model 5 = All CFQ-R items excluding the health
domain items; TPM Model 8 = All CFQ-R items excluding the health domain items + age and gender.
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diction occurs at the very severe end of the EQ-5D
spectrum, lower than the observed EQ-5D mean reported
in the self-reported FEV1 ‘severe’ group, this is likely to
have limited impact on the application of these algorithms.
It is important that the uncertainty around mapped esti-
mates should be considered when applying these values to
cost-effectiveness analysis.
It is interesting to note that the respiratory symp-
toms domain was not a significant predictor of EQ-5D
utility in any of the models. This is likely to be due to
the fact that the impact of respiratory symptoms is
captured through functioning dimensions of the CFQ-
R, which map onto the dimensions in the EQ-5D. It is
not uncommon for symptoms that are very specific to
a condition to be unrelated to utility scores. However,
given the focus of respiratory symptoms in CF trials it
may be worth exploring the potential to increase sen-
sitivity in utility scores by developing a condition-
specific preference-based measure.Limitations
Recruitment was conducted through the CF Trust
rather than clinical sites; thus diagnosis and FEV1
values were self-reported. However this method
allowed for the recruitment of a diverse range of par-
ticipants, with good age and gender variability across
severity levels, and FEV1 values in line with a CF
population [28,29]. Furthermore, the key measures
included in the present study were the EQ-5D and
the CFQ-R, these are developed to be patient-
reported, and the values reported in the present
study are in line with those previously reported in
CF [25]. A second limitation is the use of a split-
sample method for the estimation and validation of
the best fitting model. Validation of the model
should be conducted on an independent sample ra-
ther than a subset as required here due to sample
size. However, the cross-validation method employed
in this study permitted the best use of the data to
maximise the assessment of model performance.
Table 6 OLS and TPM Model 3 coefficients
OLS Model 3 TPM Model 3
Part 1 Part 2
Variable Coefficient Bootstrapped SE 95% Bootstrapped SE
(Bias-corrected)
95% Bootstrapped SE
(Bias-corrected)
95% Bootstrapped SE
(Bias-corrected)
Physical 0.00651*** (0.00141) 0.0037 0.0091 0.02836*** (0.00834) 0.0113 0.0449 0.00615*** (0.00188) 0.0027 0.0101
Role 0.00287*** (0.00057) 0.0017 0.0040 0.03285*** (0.01221) 0.0114 0.0583 0.00336*** (0.00075) 0.0019 0.0048
Emotion 0.00693*** (0.00211) 0.0028 0.0110 0.04287*** (0.01020) 0.0247 0.0637 0.00821*** (0.00277) 0.0029 0.0134
Vitality 0.00127** (0.00062) 0.0001 0.0025 0.00592** (0.00257) 0.0009 0.0112
Eat 0.00154*** (0.00053) 0.0005 0.0026 0.00206*** (0.00067) 0.0008 0.0034
Weight −0.00058** (0.00028) −0.0011 −0.00003 −0.00090** (0.00040) −0.0017 −0.0001
Digest 0.00094** (0.00044) 0.0001 0.0018 0.00106* (0.00061) −0.0001 0.0023
Physical squared −0.00004*** (0.00001) −0.0001 −0.00002 −0.00004** (0.00002) −0.0001 −0.00001
Vitality squared - - - - −0.00005* (0.00003) −0.0001 0.000003
Emotions squared −0.00004*** (0.00002) −0.0001 −0.00001 −0.00006** (0.00003) −0.0001 −0.00001
Constant −0.09898 (0.06297) −0.2178 0.0296 −0.22122*** (0.07169) −0.3604 −0.0790
OLS, ordinary least squares; TPM, two-part model; Model 3 = CFQ-R domains that are statistically significant at the 10% level + statistically significant squared terms.
SE = standard error; ***p < 0.01, **p < 0.05, *p < 0.1.
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The modelling approaches applied in this study demon-
strated that mapping functions can be applied to CFQ-R
datasets to estimate EQ-5D utility values for economic
evaluations of interventions for patients with cystic fibrosis
where EQ-5D data is not available. However when
applying these mapped estimates to cost-effectiveness
analysis, the uncertainty around the extremes of the
EQ-5D spectrum should be considered. In addition,
further research around the performance of the model
in an independent sample is recommended. Finally,
given the fact the respiratory domain was not a signifi-
cant predictor of EQ-5D utility, and the emphasis on
respiratory symptoms in CF trials, the development of a
disease specific preference based measure may also be
worth further investigation.
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